OECD gives update of key biotech indicators


Geneva – The Organisation for Economic Cooperation and Development (OECD) has published the latest comparable figures on the biotech branch in the US and several European countries . As expected, the US had the largest biotech branch with 3,492 biotech R&D firms (including 2,335 dedicated biotech companies, 75% thereof employing less than 50 staff), generating 41.8% of all PCT patent applications and spending $32.4bn on biotech R&D. Taken together, all 27 EU countries made 28.8% of the patent applications. As of 2008, France had the most biotech firms in Europe (1,067/676 thereof dedicated biotechs) and highest company R&D expenditure with $2.5bn, followed by Spain (942/ 305, R&D expenditure by biotechs (bex): $607m, public biotech expenditure (pbe): $1.1bn), Germany (593/501, bex: $1.2bn, pbe: $4.6bn), Switzerland (288/184, bex: $922m), The Netherlands (206/72, bex: $396m, pbe: $138m), Italy (197/117, bex: $360m, pbe: $94m), Ireland (167/71, bex: $302m), Norway (161/n.n., bex: $127m, pbe: $154m), Belgium 145/122 bex: $574m), Finland (141/77), Denmark (124/79, bex: $492m, pbe: $182m), Austria (121/111), Portugal (120/55 bex: $32m, pbe: $32m), the Czech Republic (93/69 bex: $51m, pbe: $88m), Estonia (30/25 bex: $12.7m), Poland (21/11 bex: $9.9m, pbe: $181m), Slovak Republic (11/8 bex: $2.4m, pbe: $12.6m), and Slovenia (10/3 bex: $20.7m, pbe: $3.4m). Biotech R&D intensity was highest in Denmark (0.43%), Switzerland (0.38%), and the US (0.37%). While most biotechs (>60%) were small (less then 50 staff), most biotechnology R&D was undertaken by larger biotechnology firms. Several countries could not meet the OECD deadline and will be included next year: Belgium, Sweden and the UK.



Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...



Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....



Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...



Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...



Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...



Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...



Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...



Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...



Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2015 BIOCOM



All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 26.04.2015

Current issue

All issues